FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Highlighting the role of hypocretin-1 in narcolepsy pathogenesis and its potential as a target for peptide-based therapies.
研究ライブラリに戻る
hypocretin-1orexin-A

Highlighting the role of hypocretin-1 in narcolepsy pathogenesis and its potential as a target for peptide-based therapies.

May 16, 2026
Share

元の論文

Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy.

Huth Alina et al.Journal of autoimmunity2024
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

Hypocretin-1: A Key Player in Narcolepsy Pathogenesis

Published: May 16, 2026 | Source: Journal of autoimmunity (2024) | Category: hypocretin-1, orexin-A

Overview

A recent review published in the Journal of Autoimmunity highlights the critical role of hypocretin-1 (also known as orexin-A) in narcolepsy pathogenesis. This finding underscores the potential for peptide-based therapies targeting this neurotransmitter to alleviate symptoms and possibly treat the condition.

Study Background

Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and, in some cases, sudden muscle weakness triggered by strong emotions (cataplexy). The exact cause of narcolepsy remains unclear, but it has been linked to genetic factors such as the presence of HLA-DQB1*06:02 allele. Additionally, patients with type 1 narcolepsy (NT1) exhibit significantly lower levels of hypocretin-1 in their cerebrospinal fluid (CSF). This review aims to provide a deeper understanding of the cellular mechanisms involved by analyzing single-cell transcriptomics data from recent-onset narcolepsy cases.

What the Research Found

The study reveals that patients with recent-onset narcolepsy, particularly those with NT1, show markedly reduced levels of hypocretin-1 in their CSF. This neurotransmitter is crucial for regulating wakefulness and sleep cycles. The review also emphasizes the strong association between narcolepsy and the HLA-DQB1*06:02 allele, which may contribute to an autoimmune response targeting hypocretin-producing neurons.

What This Means for Peptide Users

The findings suggest that restoring or enhancing hypocretin-1 levels could be a promising therapeutic approach. While current treatments focus on managing symptoms like sleepiness and cataplexy, peptide-based therapies might offer more targeted interventions by addressing the underlying pathophysiology of narcolepsy.

Limitations and Caveats

As this is a review rather than an original research paper, it does not provide new empirical data but synthesizes existing knowledge. Additionally, the focus on recent-onset cases may limit generalizability to all narcolepsy patients, including those with long-term conditions or type 2 narcolepsy (NT2) without cataplexy.

How This Compares to Previous Research

Previous studies have already established a link between hypocretin-1 deficiency and narcolepsy. However, this review adds depth by examining single-cell transcriptomics data, offering insights into the cellular changes that occur in early-stage narcolepsy. The emphasis on HLA-DQB1*06:02 further supports the autoimmune hypothesis of narcolepsy.

Our Analysis

PeptideVault's analysis indicates that while this review consolidates existing knowledge and provides valuable context for future research, it does not introduce novel empirical data. The potential for peptide-based therapies remains promising but requires further investigation through clinical trials to validate efficacy and safety profiles in diverse patient populations.

Key Takeaways

  • Critical Role of Hypocretin-1: The neurotransmitter is essential for regulating wakefulness and sleep cycles.
  • HLA-DQB1*06:02 Association: This genetic marker strongly correlates with narcolepsy, suggesting an autoimmune component.
  • Therapeutic Potential: Peptide-based therapies targeting hypocretin-1 could offer a novel approach to treating narcolepsy.

Original Source

Citation: Huth Alina, Ayoub Ikram, Barateau Lucie et al. (2024). Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy.. Journal of autoimmunity. DOI: 10.1016/j.jaut.2024.103234

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。